SION - CIK 0002036042
The table below shows Sionna Therapeutics, Inc.'s cash flow statement line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating cash flow | -$66.30M | -$52.79M |
| Capital expenditure | $377.00K | $27.00K |
| Investing cash flow | -$118.75M | -$126.91M |
| Dividends paid | - | - |
| Stock buybacks | - | - |
| Financing cash flow | $205.71M | $178.97M |
Sionna Therapeutics, Inc. reported operating cash flow of -$66.30M for fiscal year 2025. That is down 25.6% from -$52.79M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.